Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in clinically relevant patient subgroups, are reported. Eligible patients were aged ≥18 years with unresectable sta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Melanoma Res
Main Authors: Hodi, F. Stephen, Chapman, Paul B., Sznol, Mario, Lao, Christopher D., Gonzalez, Rene, Smylie, Michael, Daniels, Gregory A., Thompson, John A., Kudchadkar, Ragini, Sharfman, William, Atkins, Michael, Spigel, David R., Pavlick, Anna, Monzon, Jose, Kim, Kevin B., Ernst, Scott, Khushalani, Nikhil I., van Dijck, Wim, Lobo, Maurice, Hogg, David
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2020
Assuntos:
Original Articles: Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7757740/
https://ncbi.nlm.nih.gov/pubmed/33234846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000708
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados